Yagna PR Jarajapu, MPharm, MS, PhD, FAHA

Associate Professor
16 Sudro Hall

Phone 701.231.8843
Fax 701.231.8333

E-mail Yagna.Jarajapu@ndsu.edu 


Pharmacogenomics (PSCI417) and Neuropharmacology (PSCI 415) for Pharm D students.

Research Interests

  1. Role of the Beta-splice Variant of Telomerase Reverse Transcriptase in the Vasoreparative Dysfunction of Diabetic Stem/Progenitor Cells.
  2. Targeting Alamandine/MrgD Axis for Aging-Associated Vascular Dementia.
  3. Pharmacology of Mas Receptor(s) in the Aging-Associated Leaky Gut and Inflammation.


    2002   Ph.D.  Glasgow Caledonian University, UK  
    1998   M.Sc.  University of Strathclyde, UK   
    1993   M.Pharm. Andhra University, India   
    1990   B.Pharm Andhra University, India   

    2003 and 2006   ASPET Travel Awards.
    2001 British Pharmacological Society Travel Award for Pharmacology-2001, Vancouver, Canada.
    2001 European Society for Hypertension Travel Award.
    2001 Federation of European Pharmacological Societies (EPHAR) Travel Award.
    1997   Academy of Commonwealth Universities (ACU) and Oversees Development Administration (ODA) Shared Scholarship.
    1991   University Grants Commission (UGC) Fellowship.
    1991   Indian Drug Manufacturers Association (IDMA), G.P.Nair Award.

    Professional Appointments

    2008-2011  Asst. Instructor, Pharmacology & Therapeutics, University of Florida, Gainesville, FL.
    2005-2007  Part-Time, Technology-Scientist, Danish MyoTechnology-USA, Inc. 
    2005-2007  Post-Doctoral Associate, Wake Forest University, Winston-Salem NC.
    2002-2004  Post-Doctoral Associate, Pharmacology & Therapeutics, University of Florida, Gainesville, FL.
    1995-1997  Sr. Pharmacologist, Dr. Reddy’s Research Foundation, Hyderabad, India. 


    2020 to date    Member of the American Aging Association.
    Life member    Association of Scientists of Indian Origin in America.
    2011-2017       Member of American Association of Colleges of Pharmacy (AACP).
    2007 to date    Professional member of American Heart Association (AHA).
    2002 to date    Regular member of American Society of Pharmacology and 
                            Experimental Therapeutics (ASPET).
    2006-2011       Member of the Association for Research in Vision and 
                            Ophthalmology (ARVO).
    1998-2007       Regular member of the British Pharmacological Society (BPS).
    1998-2004       Member of British Physiological Society.
    1995-1997       Member of Indian Pharmacological Society (IPS).
    Life member    Indian Pharmaceutical Graduates Association (IPGA).

    Selected Publications

    Chittimalli K, Jahan J, Sakamuri A, McAdams ZL, Ericsson AC, Jarajapu YP. (2023). Restoration of gut barrier integrity and restructuring of the gut microbiome in aging by Angiotensin-(1-7). Clin Sci (London). 137(11):913-930.

    Jarajapu YP. (2021). Targeting ACE2/Ang-(1-7)/Mas receptor in the vascular progenitor cells for cardiovascular diseases. Mol Pharmacol. 99(1):29-38.

    Joshi S, Montes de Oca I, Meghrabi A, Yang CL, Quiroz Olvera J, Garcia CA, Jarajapu YP. (2021) ACE2 Gene Transfer Ameliorates Vasoreparative Dysfunction in CD34+ Cells Derived from Diabetic Older Adults. Clin Sci (London). 135(2):367-385.

    Joshi S, Mahoney S, Jesmin J, Pitts L, Hackney KJ, Jarajapu YP. (2020) Blood flow restriction exercise stimulates mobilization of hematopoietic stem/progenitor cells and increases the circulating ACE2 levels in healthy adults. J Appl Physiol (1985). 128(5):1423-1431.

    Joshi S, Wollenzien H, Leclerc E, Jarajapu YP. (2019). Hypoxic Regulation of Angiotensin-Converting Enzyme 2 and Mas Receptor in Human CD34+ Cells. J Cell Physiol. 234(11):20420-20431.

    Vasam G, Joshi S, Thatcher SE, Bartelmez SH, Cassis LA, Jarajapu YP. (2017). Reversal of bone marrow mobilopathy and enhanced vascular repair by Angiotensin-(1-7) in diabetes. Diabetes. 66(2):505-518.

    Follow this link for the full list of publications: http://www.ncbi.nlm.nih.gov/pubmed?term=yagna%20OR%20jarajapu

    Current Funding Support

    National Institutes of Health and American Heart Association.

    Top of page